WHY IT MATTERS: If Texas moves toward a per se THC limit for driving, patients using cannabis for legitimate medical purposes could face DUI charges even when they are not functionally impaired, because THC and its metabolites can persist in blood well beyond any period of active intoxication. CLINICAL OVERVIEW: Cannabis-impaired driving remains a serious public safety challenge because THC affects psychomotor function, reaction time, and divided attention in ways that meaningfully increase crash risk. Unlike alcohol, there is no validated per se blood THC threshold that reliably correlates with functional impairment, making enforcement both scientifically and legally complicated.
Hemp article tells us why WI needs government regulations | Letter – Milwaukee Journal Sentinel
WHY IT MATTERS: If you are buying hemp-derived CBD or delta-8 products at a gas station or retail store in Wisconsin, there is currently no reliable guarantee that what is on the label matches what is in the product, including the THC content. CLINICAL OVERVIEW: Hemp-derived products sold legally in retail settings are not subject to the same testing and labeling requirements as products sold through licensed cannabis dispensaries, creating a significant gap in consumer protection. When products contain more THC than disclosed or permitted, consumers have no reliable way to know what they are actually ingesting, which raises meaningful concerns about unintended intoxication, drug interactions, and impaired driving.
In the Mix: 8 More Articles — February 28, 2026
8 cannabis articles reviewed and scored below the CED clinical relevance threshold in the February 28, 2026 feed update. Organized by topic with summaries and source links.
Expert breaks down hidden dangers of doctors prescribing medical marijuana – UNILAD
WHY IT MATTERS: Patients using medical cannabis should know that a formal diagnosis or physician recommendation does not eliminate the risk of developing Cannabis Use Disorder, and open communication with your prescribing doctor about frequency and dosage is essential for long-term safety. CLINICAL OVERVIEW: Cannabis Use Disorder is a clinically recognized condition characterized by continued use despite negative consequences, with estimated prevalence rates ranging from roughly 9% of all users to as high as 33% among daily users. The medicalization of cannabis has created a complex dynamic where legitimate therapeutic access may, in some patients, lower the perceived risk of the substance and contribute to problematic use patterns.
Teen Cannabis Use May Double Your Risk of Psychosis and Bipolar
WHY IT MATTERS: Parents, pediatricians, and young people themselves need to understand that the risk calculus for cannabis is not the same at 15 as it is at 35, and that psychosis and bipolar disorder are not rare or abstract outcomes but life-altering diagnoses with serious long-term consequences. CLINICAL OVERVIEW: The relationship between adolescent cannabis use and psychiatric outcomes has been a subject of serious scientific inquiry for decades, with converging evidence suggesting that exposure during neurodevelopmental windows carries meaningfully different risks than adult-onset use. The adolescent brain, particularly the prefrontal cortex and limbic system, undergoes significant synaptic pruning and maturation through the mid-twenties, and the endocannabinoid system plays a direct regulatory role in that process.
Daily Digest: Last 24 Hours: CHS Awareness, Prenatal Risk, and the Endocannabinoid System’s Expanding Reach — February 28, 2026
✦ New CED Clinical Relevance#72Notable Clinical InterestEmerging findings or policy developments worth monitoring closely. SafetyResearchMental HealthPediatrics Why This MattersCannabinoid hyperemesis syndrome and prenatal cannabis exposure represent clinically significant adverse outcomes that warrant...
Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know
WHY IT MATTERS: Patients and clinicians hoping for a targeted pharmacological tool to manage THC overconsumption or cannabis use disorder may face longer timelines before any such option becomes available. CLINICAL OVERVIEW: AEF0117 is a first-in-class CB1 receptor signaling inhibitor developed by Aelis Farma, designed to selectively block certain downstream effects of THC without fully antagonizing the receptor, representing a novel pharmacological approach to cannabis use disorder and THC-related adverse effects. The withdrawal of a THC interaction trial is a meaningful setback because interaction studies are critical for characterizing how AEF0117 behaves in the presence of active THC, which is the precise clinical scenario the drug is meant to address.
DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL … – StreetInsider
WHY IT MATTERS: If thin-film CBD delivery is confirmed to offer superior and more consistent bioavailability compared to traditional oral products, patients may need to recalibrate their doses when switching formats to avoid unintended underdosing or overdosing. CLINICAL OVERVIEW: Sublingual and buccal thin-film delivery systems represent a meaningful departure from conventional oral cannabinoid formats because they bypass first-pass hepatic metabolism, potentially improving both the speed of onset and the consistency of systemic absorption. CBD delivered through mucoadhesive strip technology may achieve higher bioavailability compared to standard oil-based or capsule formulations, which are notoriously variable due to differences in fed versus fasted states and individual digestive physiology.
Cannabis use, anxiety and depression are all on the rise in Canada: study – CTV News
WHY IT MATTERS: Patients using cannabis to manage anxiety or depression should be aware that without proper medical guidance on strain selection, THC-to-CBD ratios, and dosing, cannabis may be worsening the very symptoms they are trying to treat. CLINICAL OVERVIEW: Research from Canada is highlighting a parallel rise in cannabis use alongside increasing rates of anxiety and depression, raising important questions about the direction of causality and the role cannabis may be playing in mental health outcomes. The relationship between cannabis and mood disorders is complex, as individuals may be turning to cannabis to self-manage psychological distress while the substance itself, particularly high-THC products, can worsen anxiety and depressive symptoms over time.
Marijuana Use & Dangers for Adolescents & Young Adults
WHY IT MATTERS: Parents, school counselors, and young people themselves should understand that regular cannabis use during adolescence is not a benign habit but a potential accelerant for mental health problems that may require professional intervention. CLINICAL OVERVIEW: Adolescents and young adults represent a particularly vulnerable population when it comes to cannabis use, largely because the brain continues developing well into the mid-twenties, making it highly susceptible to the neurological effects of THC during this window. When cannabis use disorder co-occurs with underlying mental health conditions such as anxiety, depression, or early psychotic spectrum disorders, the clinical picture becomes substantially more complex and harder to treat.